CMI sequences as an early marker for the future development of cancer, atherosclerosis, diabetes and diseases of the CNS and as a target for the treatment and prevention of these diseases

C2MI polynucleic acids and related technologies are used to diagnose and treat diseases linked to herpes-type viruses and bovine milk factors, addressing chronic inflammation and immune response, thereby mitigating disease progression.

AU2020210852B2Pending Publication Date: 2026-07-23DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS
Filing Date
2020-01-24
Publication Date
2026-07-23

Smart Images

  • Figure 00000055_0000
    Figure 00000055_0000
  • Figure 00000059_0000
    Figure 00000059_0000
  • Figure 00000071_0000
    Figure 00000071_0000
Patent Text Reader

Abstract

Described are CMI (Cow Milk Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as early markers for the future development of cancer, diabetes, atherosclerosis and diseases of the CNS (Multiple sclerosis MS, Prion-linked diseases, amyotrophic lateral sclerosis, transmissible spongiforme encephalitis, Parkinson's disease, Alzheimer disease) and should represent targets for treatment and prevention.
Need to check novelty before this filing date? Find Prior Art